Hidradenitis Suppurativa Market

Hidradenitis Suppurativa: Introduction

• Over the past few decades, there has been a steady increase in the occurrence of Hidradenitis Suppurativa worldwide. Dermatologists estimate that 1-4% of the general population has Hidradenitis Suppurativa in one form or another. However, only a small percentage of them have been properly diagnosed and treated thus far. The incidence of HS is expected to rise significantly in the near future due to changes in lifestyle that make people more likely to become obese and smokers more vulnerable.
• Finding more positive instances will be made easier with access to improved screening and diagnostic methods. Patients can receive prompt management that can help reduce the disease's course since increased clinical awareness leads to earlier therapies. In many nations, insurance coverage for HS therapies is also expanding at the same time.
• Together, these elements suggest that there is an increasing need for efficient therapeutic solutions that can reduce symptoms and enhance quality of life. In response to this demand, pharmaceutical firms and medication makers are increasing their investments in cutting-edge research initiatives. For the foreseeable future, the growing prevalence of HS worldwide will remain a significant market driver.

Development of Targeted Biologics Improves Patient Outcomes

• For a long time, treating hidradenitis suppurativa has been extremely difficult due to incomplete knowledge of its pathogenic origins. A significant number of patients suffered from recurrent illness flare-ups, tunneling, and scarring over time as a result of the lack of previously authorized targeted therapy. The poorly treated chronic medical condition has a major negative impact on their physical, emotional, and social well-being.
• The introduction of anti-TNF alpha therapies such as biosimilars, adalimumab, and infliximab has yielded revolutionary outcomes. When given these targeted biologics, the majority of patients in many clinical studies experienced remission, a clinically meaningful response, and improvements in their quality of life. For both - mild and severe cases of HS, their unique method of reducing hyperactive immune cells has resulted in long-term disease control and symptom relief.
• Pharmaceutical firms are encouraged by this accomplishment to keep spending money on innovative biologic treatments with better safety profiles, dosing regimens, and pharmacological characteristics. There are a few excellent pipeline candidates that could become the finest therapies available. Patient outcomes are looking better than ever because to therapy choices that now address the underlying immunological issues. The management strategy and future market developments will undoubtedly be revamped by this move towards highly effective, focused biologics.

Untapped Potential in Developing Regions with Expanding Healthcare Infrastructure is Expected to Drive Overall Hidradenitis Suppurativa Market

• One key opportunity for growth of the hidradenitis Suppurativa market is the untapped potential found in emerging countries with growing healthcare infrastructure and treatment availability. This constitutes a significant unmet need, as improved access to care allows more at-risk patient populations to be identified and treated appropriately.
• As the middle class rises in countries such as China, Brazil, India, and others, private healthcare industries' potential to supply novel, inexpensive therapies grows rapidly.
• First-mover pharmaceutical businesses and providers who collaborate with local clinicians, educators, and insurers stand to benefit as these emerging but significant markets mature.

Prescribers Preferences for Hidradenitis Suppurativa Market to Boost Market Growth

• Hidradenitis suppurativa (HS) is often treated step by step, depending on the severity and stage of the disease. For moderate HS (stage 1), doctors usually offer topical therapies such as clindamycin 1% gel (Cleocin T). If topical treatments fail, oral antibiotics like doxycycline 100 mg (Doxycycline Hyclate) may be given.
• For moderate HS (stage 2), first-line systemic therapies include oral antibiotics and additional procedures such as intralesional corticosteroid injections for decreasing inflammatory nodules and abscesses. Tetracycline 500 mg (Sumycin), minocycline 100 mg (Minocin), and erythromycin 500 mg (Ery-Tab) are three commonly used antibiotics.
• Biologics, either alone or in combination with immunosuppressants, are frequently used to treat severe HS (stage 3). Adalimumab 40 mg injections (Humira), a TNF-alpha inhibitor, and ustekinumab 45/90 mg injections (Stelara), a monoclonal antibody that targets IL-12 and IL-23, are popular biologic options. To optimize the efficiency of biologics, immunosuppressants such as azathioprine 50-150 mg (Imuran) are used in combination.
• When deciding on a course of action, prescribers examine insurance coverage, cost, safety/side-effects, patient adherence, and previous therapy responses. Overall, treatment regimens are adjusted to each case's specific disease burden and severity for establishing remission and preventing recurrence or advancement of Hidradenitis Suppurativa.

By Treatment Type, the biologics segment accounted for the largest share of the hidradenitis Suppurativa industry

• In terms of treatment, biologics accounted for 55.7% of the market in 2024 due to their superior efficacy and focused approach to treating Hidradenitis Suppurativa. Biologics such as tumor necrosis factor inhibitors help in modulating the immune response that produces inflammation and symptoms in Hidradenitis Suppurativa patients.
• Biologics provide superior control over illness symptoms with little side-effects as they target specific phases in the immunological pathway rather than inhibiting it in general. Biologics' targeted nature promises long-term remission for patients by addressing the underlying source of the ailment.
• Furthermore, biologics frequently produce results quickly, thereby providing faster symptom alleviation to individuals suffering from acute pain and hidradenitis Suppurativa infections. Due to their excellent success rates in reducing disease severity scores and quality of life, biologics have become the recommended therapy option for moderate to severe cases of hidradenitis Suppurativa.
• However, in June 2023, the European Commission authorized COSENTYX, an IL-17A monoclonal antibody, for people with active moderate-to-severe hidradenitis Suppurativa who have not responded well to conventional systemic therapy. The FDA authorized COSENTYX for the same indication in October 2023. More recently, in April 2024, UCB reported that the European Commission has approved BIMZELX for use in people with active moderate-to-severe hidradenitis Suppurativa who had not responded well to conventional systemic therapy.

North America to Lead the Hidradenitis Suppurativa Market

• North America dominates the hidradenitis suppurativa market due to the rapid adoption of novel procedures in the region. Furthermore, increasing presence of the major key players and well-established healthcare infrastructure will accelerate the market's growth rate in this region. Moreover, growing number of product approvals for the treatment of Hidradenitis Suppurativa are expected to fuel the market growth. For instance, in November 2024, UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). BIMZELX is the first and only approved medicine designed to selectively inhibit interleukin 17F (IL-17F) in addition to interleukin 17A (IL-17A).
• Asia-Pacific is predicted to increase over the forecast period due to the increasing number of generic manufacturers and government initiatives in the region. Furthermore, the expansion of healthcare infrastructure will accelerate the market's growth rate in this region.

Key Players Operating in the Global Hidradenitis Suppurativa Market

The major players operating in the global market are focusing on advancements in research and development to meet the rising demand for Hidradenitis Suppurativa treatment. Moreover, service providers are entering into partnerships for the development of innovative products.

Key players operating in the global hidradenitis suppurativa market include:

• AbbVie Inc
• Pfizer Inc.
• Novartis AG
• UCB Pharma
• Eli Lilly and Company
• Sanofi
• MoonLake TX
• UNION therapeutics A/S
• ACELYRIN, INC
• Other Prominent Players

Market Segmentation

• By Treatment Type:
  • Pharmacological Treatment
    • Biologics & Biosimilars
    • Antibiotics
    • NSAIDs
    • Others (Corticosteroids, etc.)
  • Non-pharmacological Treatment
    • Hormonal Therapy
    • Botulinum toxin
    • Laser Treatment
    • Others (Surgical Procedures, etc.)
• By Indication:
  • Folliculitis
  • Pimples
  • Boils
  • Others (Deep Acne, etc.)
• By Treatment Availability:
  • Pharmacological
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Non-pharmacological
    • Hospitals
    • Dermatology Clinics
    • Research Institutes
• By Region:
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa